JAK2 and Thrombocytopenia: JAK2 deficient could be barely seen among humans, which may be due to the fact that JAK2 deficiency is lethal in early life [21], and downregulation of JAK2 is mainly mentioned in the therapy for MPD, in which thrombocytopenia becomes a dose-limited factor to the use of JAK2 inhibitors.